Major Disease Coverage In China Presents An Opening For Commercial Insurers
This article was originally published in PharmAsia News
New government guidelines for major disease coverage will leverage commercial insurers, and drive patient volume and demand for pharmaceuticals, analysts say.
You may also be interested in...
As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.
China insurance giant snatches up stakes in Japanese pharma and a traditional Chinese medicines maker with a $465m spending spree.
With vaccines perhaps the ultimate weapon to fight the coronavirus, a developer in China sees a big chunk of investment with potentially more companies to see funding coming.